Barclays PLC restated their equal weight rating on shares of Quest Diagnostics Inc (NYSE:DGX) in a report issued on Sunday, April 23rd. The firm currently has a $100.00 price objective on the medical research company’s stock, up from their prior price objective of $98.00.

Several other equities analysts also recently issued reports on the stock. Deutsche Bank AG reaffirmed a buy rating and set a $115.00 price target (up previously from $108.00) on shares of Quest Diagnostics in a research note on Sunday, April 23rd. Raymond James Financial, Inc. raised shares of Quest Diagnostics from a market perform rating to an outperform rating and set a $116.00 target price for the company in a research note on Friday, April 21st. Mizuho reissued a buy rating and set a $90.00 target price (down previously from $103.00) on shares of Quest Diagnostics in a research note on Friday, April 14th. FBR & Co lifted their target price on shares of Quest Diagnostics from $103.00 to $110.00 and gave the stock an outperform rating in a research note on Wednesday, April 12th. Finally, Zacks Investment Research raised shares of Quest Diagnostics from a hold rating to a buy rating and set a $110.00 target price for the company in a research note on Wednesday, March 29th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $106.58.

Shares of Quest Diagnostics (NYSE:DGX) opened at 106.55 on Friday. The stock’s 50 day moving average price is $103.31 and its 200-day moving average price is $95.35. The firm has a market capitalization of $14.58 billion, a PE ratio of 21.45 and a beta of 0.68. Quest Diagnostics has a 12 month low of $75.20 and a 12 month high of $108.21.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, April 20th. The medical research company reported $1.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.15. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.87 billion. Quest Diagnostics had a net margin of 8.56% and a return on equity of 14.61%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.12 earnings per share. On average, equities analysts anticipate that Quest Diagnostics will post $5.56 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was published by Marea Informative and is owned by of Marea Informative. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at http://www.mareainformativa.com/quest-diagnostics-dgx-equal-weight-rating-reiterated-at-barclays-plc/111857/.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 24th. Investors of record on Monday, July 10th will be issued a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a yield of 1.69%. The ex-dividend date is Thursday, July 6th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.00%.

In related news, Director Jenne K. Britell sold 6,111 shares of the business’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $104.03, for a total transaction of $635,727.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Catherine T. Doherty sold 7,162 shares of the business’s stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $98.28, for a total transaction of $703,881.36. Following the transaction, the senior vice president now owns 87,809 shares in the company, valued at $8,629,868.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,213 shares of company stock worth $5,732,460. 1.50% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DGX. Parkwood LLC bought a new stake in shares of Quest Diagnostics during the third quarter valued at approximately $278,000. Regentatlantic Capital LLC raised its stake in shares of Quest Diagnostics by 14.7% in the third quarter. Regentatlantic Capital LLC now owns 11,921 shares of the medical research company’s stock valued at $1,009,000 after buying an additional 1,525 shares in the last quarter. Boston Advisors LLC raised its stake in shares of Quest Diagnostics by 30.1% in the third quarter. Boston Advisors LLC now owns 71,556 shares of the medical research company’s stock valued at $6,056,000 after buying an additional 16,576 shares in the last quarter. Conning Inc. raised its stake in shares of Quest Diagnostics by 1.2% in the third quarter. Conning Inc. now owns 10,223 shares of the medical research company’s stock valued at $865,000 after buying an additional 120 shares in the last quarter. Finally, Commonwealth Equity Services Inc raised its stake in shares of Quest Diagnostics by 0.3% in the third quarter. Commonwealth Equity Services Inc now owns 16,112 shares of the medical research company’s stock valued at $1,364,000 after buying an additional 52 shares in the last quarter. Institutional investors and hedge funds own 87.71% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

12 Month Chart for NYSE:DGX

Receive News & Stock Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related stocks with our FREE daily email newsletter.